aTyr Pharma to Participate at the Piper Jaffray 29th Annual Healthcare Conference
November 21 2017 - 8:00AM
aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged
in the discovery and development of immuno-modulatory protein
therapeutics to treat patients suffering from rare, severe,
immune-mediated diseases, as well as various cancers, today
announced that Sanjay Shukla, M.D., M.S., President and Chief
Executive Officer, will participate in a fireside chat at the 29th
Annual Piper Jaffray Healthcare Conference on Wednesday, November
29, 2017 at 8:00 a.m. Eastern Time. The conference will be held at
the Lotte New York Palace Hotel in New York, NY.
Links to a live audio webcast and replay of the fireside chat
discussion may be accessed on the aTyr website events page at:
http://investors.atyrpharma.com/events-and-webcasts. An audio
replay will be available for 90 days following the event.
About aTyr Pharma
aTyr Pharma is engaged in the discovery and development of
innovative medicines for patients using its knowledge of
Physiocrine biology, a newly discovered set of immunological and
physiological pathways. To date, aTyr has generated three
innovative and unique development programs based on its knowledge
of the Resokine pathway to treat patients suffering from rare,
severe, immune-mediated diseases, as well as various cancers.
aTyr’s two lead programs, Resolaris and iMod.Fc, are agonists of
the Resokine pathway designed to temper immune engagement in
diseases characterized by excessive immune cell involvement. aTyr’s
third program, ORCA, represents a preclinical research program that
targets a novel, proprietary immuno-oncology pathway using
antibodies to enhance the immune response in tumor settings. aTyr
has built an intellectual property estate, to protect its pipeline,
comprising over 220 issued patents or allowed patent applications
that are owned or exclusively licensed, including over 300
potential Physiocrine-based protein compositions. For more
information, please visit http://www.atyrpharma.com.
Contact:Mark Johnson Sr.
Director, Investor Relationsmjohnson@atyrpharma.com858-223-1163
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Apr 2023 to Apr 2024